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1. Introduction 
Tuberculosis (TB) was responsible for millions of human deaths in the past, when there 
were no adequate treatment methods for infected patients. Introduction of chemotherapy 
and prophylactic measures led to drastic death reduction, which was maintained for various 
decades. However, “the good times” waned, as this disease became worldwide recognized 
as the one responsible for most human deaths caused by a single infectious agent: 
Mycobacterium tuberculosis (MTB). TB resumption is basically a consequence of anthropic 
factors, such as the recent HIV/AIDS pandemic and the development of drug resistant 
strains (stemmed from inappropriate treatments and/or patient non-compliance).  
International attention has turned toward the evolving burden of multi-drug resistant 
tuberculosis (MDR TB) that has emerged in epidemic proportions in the wake of 
widespread HIV infection in the world's poorest populations, including sub-Saharan 
Africa. Extensively drug-resistant TB (XDR TB) was first reported in 2006 but has now 
been documented on six continents [WHO the global laboratory initiative]. These trends 
are critically important for global health, since drug-resistant TB mortality rates are high 
and second-line agents for the treatment of drug-resistant TB are less potent and less 
tolerable than first-line therapies.  
Global control of tuberculosis is hampered by slow, insensitive diagnostic methods, 
particularly for the detection of drug-resistant forms and in patients with human 
immunodeficiency virus infection. Failure to quickly and effectively recognize and treat 
patients with drug-resistant tuberculosis (TB), particularly MDR and XDR tuberculosis, 
leads to increased mortality, nosocomial outbreaks and resistance to additional 
antituberculosis drugs. We believe that early detection is essential to reduce the death rate 
and interrupt transmission, but the complexity and infrastructure needs of sensitive 
methods limit their accessibility and effect.  
Therefore, there’s a critical need for methods that can rapidly detect M. tuberculosis and 
identify drug-resistant cases to optimize TB treatment with appropriate drugs.  
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The present review describes the main techniques used to detect TB and related resistant 
strains as well as the issues and challenges associated with implementing molecular 
techniques in Morocco to enhance the National Program against Tuberculosis.  
2. History of tuberculosis 
2.1 Looking at past: Before the discovery of BCG 
First reference of a disease similar to TB in humans dates back to ancient Egypt. 
Examinations of mummies and tomb paintings reveal that tuberculosis was present at that 
time (around 5000 BC). The ancient Egyptian paintings portray spinal tuberculosis, 
indicating the presence of the disease. The reference of a disease called “phthisis” is found in 
ancient Greek literature by Hippocrates. In 1680, F. Sylvius carried out anatomic-pathologic 
studies in pulmonary nodules from TB patients, which he named as “tubercula”, observing 
their evolution to lung ulcers (cavities). However, most of the great pathologists of his time 
believed that these knots were some type of tumor or abnormal gland, rejecting any 
probable infectious origin. The first credible speculation of the infectious nature of TB was 
performed by B. Marten, who proposed in 1722 that TB could be caused by micro-
organisms. R. Morton used the term “consumption” to specifically denote TB, and finally, in 
1819, the inventor of the stethoscope, R. Laennec identified for the first time the TB 
manifestation unit. As the disease became completely established among every European 
social level, afflicting many of the intellectual and artists of the continent by the half of the 
XIX century, TB was romanticized, as typical symptoms like thin and pale faces of the 
infected ones became signs of beauty.  
In 1865, JA Villemin demonstrated formally that TB is a contagious disease; although his 
experimentation could be effectively reproduced in rabbits, the finding was ignored by his 
contemporaries for a long time. 
2.2 BCG as prophylactic strategy 
One of the greatest works on TB was performed in 1882 by Robert Koch, who isolated and 
cultured M. tuberculosis from crushed tubercles. His experimental work identified the 
bacterium as the TB etiological agent (Bloom & Murray 1992, Daniel 1997). In August of 
1890, during The First Ordinary Session of the International Medical Congress, in Berlin, 
he announced the discovery of a TB therapeutic drug. Three months later, M. 
Wochenschkift published a new statement of Koch, revealing that although interested in 
the therapeutic properties of his findings, he observed that the referred liquid, named 
tuberculin, could be useful as a diagnostic tool to detect the disease due to the intensified 
reaction developed by sick animals inoculated with this drug, as no measurable effect was 
ever observed in healthy ones. This concept was perpetuated for several years, until it was 
observed that even healthy animals could react to the drug. The veterinarians clarified the 
fact by demonstrating that the healthy ones could be simply infected, although not ill. As 
a result, it was established that M. tuberculosis-infected animals will react to tuberculin 
infusion, whereas the non-infected ones will not. This drug, the first industrialised one, 
was called old tuberculin; subsequently, other tuberculins were produced, such as 
purified protein derivate (PPD), PPD-S, and PPD RT23, among others (Vaccarezza 1965, 
Ruffino- Netto 1970). The tuberculin skin test became the principal tool for infection 
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diagnosis. In the same period, Koch developed staining methods for the identification of 
the bacillus; these techniques were subsequently improved by the bacteriologist “Paul 
Ehrlich”, whose method for detection of the bacillus provided the basis for the 
development of the Ziehl-Nielsen staining, which still is an important tool to diagnose TB. 
Koch’s discovery allowed researchers to focus their efforts on the development of new 
and more efficient therapies to treat TB patients. One of the first attempts to fight the 
disease in 1884 was the introduction for TB patients of “sanatorium cure” concept, where 
the patients were isolated and taken care of, the treatment was based on rest, fresh air and 
a healthy diet. 
In 1896, the bacteriologist T. Smith demonstrated that bovine TB was not caused by M. 
tuberculosis, but rather by another species, M. bovis. Twelve years later, the scientist-couple 
A. Calmette and C. Guérin isolated the bovine variant from its host and grew the bacilli in 
dispersed culture. By the 39th passage they observed a morphological variant that was 
avirulent in several animal models and which conferred immunological protection against 
subsequent challenges with virulent M. tuberculosis. Thirteen years of experimentation led to 
the obtaining of the 231st passage, the variant that was administered for the first time in 
humans (orally), as an attempt to immunize a child whose mother died in childbirth victim 
of TB. Currently known as BCG (Bacille Calmette-Guérin), the “intradermal” vaccine has 
become widely used to combat TB; it relies on a prophylactic administration of live 
attenuated bacilli to children. 
2.3 Tuberculosis chemotherapy  
Significant progress has been made in TB chemotherapy. In the pre-antibiotic era, before 
1940, there were no drugs against the disease. The tuberculosis treatment at the time 
consisted mainly of cod liver oils (which by the way, include vitamin D), bed rest and fresh 
air. 
The first TB drug, Streptomycin (SM), was discovered in 1944. It was followed by Para-
aminosalicylic acid (PAS), which was discovered in 1946. Then, in 1952, two important first-
line TB drugs were discovered, Isoniazid (INH) and Pyrazinamide (PZA). The last TB drug 
discovered was Rifampin, in 1963. 
Hence, the introduction of TB chemotherapy in 1950’s led to a significant decline in the 
incidence of the disease, particularly in developed countries. This reduction has prompted 
some public health professionals, mainly in the US, to claim that tuberculosis no longer 
poses a problem in developed countries. They have even eliminated many TB control 
programmes in the country. However, in the late 1980’s, a major outbreak of MDR-TB 
occurred in New York City, which has cost USD 1 billion to control. This outbreak has led to 
a renaissance in TB research. 
2.4 Drug combinations 
It is noteworthy that the current TB therapy is based on the principle of drug combination. 
The first advantage of using drug combinations is that it reduces drug resistance. A second 
advantage of drug combinations is that they can enhance the efficacy of the therapy. This 
point is illustrated by the Mitchison hypothesis, also referred to as the Special Bacterial 
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Populations Theory. According to this theory, TB bacteria found in the lesions consist of 
four different sub-populations. Population A, which is actively growing, is killed by 
Isoniazid. In case of Isoniazid resistance, it is killed by Rifampicin, Streptomycin, or 
Ethambutol. Population B, which has a slower metabolism, is killed by Rifampicin. 
Population C, which resides in an acidic environment, is killed by PZA. Finally, population 
D is a dormant population, and there are currently no drugs that can effectively kill this 
population (Paramasivan, 2005). 
2.5 Directly Observed Treatment Short course strategy 
TB persists as a global public health problem and the main focus for the twentieth century is 
firstly to cure the individual patient and secondly to minimise the transmission of M. 
tuberculosis to other persons (WHO, 2003; Blumberg, 2003). The ongoing TB problem has 
been due to the neglect of TB control by governments, inadequate access and infrastructure, 
poor patient adherence to medication, poor management of TB control programs, poverty, 
population growth and migration, and a significant rise in the number of TB cases in HIV 
infected individuals. Treatment of patients with TB is done according to the following five 
key components of the Directly Observed Treatment Short course (DOTS) strategy 
recommended by World Health Organization (WHO) (Walley, 1997): 
 Government commitment 
 Case detection by sputum smear microscopy 
 Standardised treatment regimen of six to eight months 
 A regular, uninterrupted supply of all essential anti-TB drugs 
 A standard recording and reporting system. 
Since the introduction of the DOTS strategy in the early ‘90s by the WHO, considerable 
progress has been made in global TB control (Sterling, 2003). In 1997, the estimated average 
treatment success rate worldwide was almost 80%. However, less than 25% of people who 
are sick with TB are treated through the DOTS strategy (Bastian, 2000). A total of 180 
countries (including both developed and developing countries) had adopted and 
implemented the DOTS strategy by the end of 2002 and 69% of the global population are 
living in areas covered by the DOTS strategy (Blumberg, 2003). However, even though 
DOTS programs are in place, treatment success rates are very low in low income countries 
due to poor management of TB control programs and patient non-compliance (Lienhardt 
and Ogden, 2004; Bastian, 2003). Furthermore, the effectiveness of DOTS is facing new 
challenges with respect to the spread and increase of MDR-TB and the co-epidemic of 
TB/HIV (WHO, 2003). Since 1999, WHO and partners have addressed these new challenges 
and have developed DOTS-Plus strategy which prevent further development and spread of 
MDR-TB and help to manage MDR-TB using second line drugs in low- and middle-income 
countries within DOTS strategy. Morocco joined the global project in 2004 and carried out 
its first simultaneous survey on primary and acquired drug resistance in tuberculosis 
patients exactly according WHO/IUATLD recommendations.  
Subsequently, 41 million of TB patients have been successfully treated in DOTS programs 
and up to 6 million lives saved since 1995. Moreover, 5 million more lives could be saved up 
to 2015 by fully funding and implementing The Global Plan to Stop TB 2011-2015. 
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3. Epidemiology of tuberculosis  
3.1 Tuberculosis throughout the world: A catastrophic situation  
More than two billion people, equal to one third of the world’s total population, are infected 
with TB bacilli. A total of 1.7 million people died from TB in 2009 (including 380 000 people 
with HIV), equal to about 4700 deaths a day. TB is a disease of poverty, affecting mostly 
young adults in their most productive years. The vast majority of TB deaths are in the 
developing world, with more than half occurring in Asia. There were 9.4 million new TB 
cases in 2009, of which 80% were in just 22 countries. Per capita, the global TB incidence rate 
is falling, but the rate of decline is very slow (less than 1%) (Wilson, 2011).  
TB is a worldwide pandemic. Among the 15 countries with the highest estimated TB 
incidence rates, 13 are in Africa, while a third of all new cases are in India and China. There 
were an estimated 440 000 new MDR-TB cases in 2008 with three countries accounting for 
over 50% of all cases globally: China, India and the Russian Federation (WHO, 2010). 
Extensively drug-resistant TB (XDR-TB) occurs when resistance to second-line drugs 
develops. It is extremely difficult to treat and cases have been confirmed in more than 58 
countries. The world is on track to achieve two TB targets set for 2015: 
 The Millennium Development Goal, which aims to halt and reverse global incidence (in 
comparison with 1990);  
 The Stop TB Partnership target of halving deaths from TB (also in comparison with 
1990).  
3.2 Tuberculosis status in Morocco 
During last years, the incidence of TB has stagnated and is reported to be 81 per 100,000 
overall. However, the incidence was significantly higher in several urban areas, or “hot 
spots”: Casablanca, Tangier and Rabat (together 43% of all notified cases in 2010). Statistical 
data show that 59% of TB patients are male and 65% are 15-34 years old. Of the roughly 
28,000 new TB cases reported annually, 12% are re-treatment cases. Moreover, the 
prevalence of tubeculosis in HIV individuals is 1.7% in 2008 (Dooley, 2010, WHO, 2010). The 
prevalence of MDR TB is 0.5% within new cases and reaches 12.2% among previously 
treated patients with failure treatment, relapse or chronical cases (Othmani, 2003; WHO, 
2010). 
National TB treatment guidelines in 2007 and 2008 recommended a Category I treatment 
regimen – 2 months of INH, RIF, PZA, and SM followed by 4 months of RIF and INH 
(2SHRZ/4RH) – for new smear-positive cases and a Category II regimen – 
2HRZES/1RHEZ/5RHE (E = Ethambutol) – for re-treatment cases. By the beginning of 
2009, ethambutol has replaced streptomycin in Category I regimen. 
The follow up of tuberculosis which lasts from 6 to 18 months is done in specialised centres 
of TB diagnosis of the ministry for Health. The late consultations and the no observance of 
treatments are responsible for TB resistance in Morocco. To strengthen its efforts, the 
ministry for Health is planning to carry a national plan of acceleration of the fight against 
tuberculosis. 
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4. Drug resistance 
4.1 Drug resistance and global surveillance: History 
Shortly, after the first anti-tuberculosis (TB) drugs were introduced, streptomycin (STR), 
para-aminosalicylic acid (PAS) and isoniazid (INH), resistance to these drugs was observed 
in clinical isolates of Mycobacterium tuberculosis (Crofton and Mitchison, 1948). This led to the 
need to measure resistance accurately and easily. The Pasteur Institute introduced the 
critical proportion method in 1961 for drug susceptibility testing in TB and this method 
became the standard method of use (Espinal, 2000; 2003). Studies on drug resistance in 
various countries in the 1960s showed that developing countries had a much higher 
incidence of drug resistance than developed countries (Espinal, 2000; 2003). By the end of 
the 1960s rifampicin (RIF) was introduced and with the use of combination therapy, there 
was a decline in drug resistant and drug susceptible TB in developed countries. This led to a 
decline in funding and interest in TB control programs. As a result, no concrete monitoring 
of drug resistance was carried out for the following 20 years (Espinal, 2000; 2003). The 
arrival of HIV/AIDS in the 1980s resulted in an increase in transmission of TB associated 
with outbreaks of multidrug- resistant TB (MDR-TB) (Edlin, 1992; Fischl, 1992). In the early 
1990s drug resistance surveillance was resumed in developed countries, but the true 
incidence remained unclear in the developing world (Cohn, 1997).  
The emergence of MDR TB is the third epidemic, complicating the epidemics of acquired 
immune deficiency syndrome (AIDS) and tuberculosis, and is requiring urgent attention to 
achieve more rapid diagnosis, to develop new therapeutic regimens and to address the 
social and hospital environment to care for these patients ( Neville, 1994). 
4.2 Primary and acquired resistance: Definition and data  
WHO estimated that 50 million people were infected with drug resistant MTB. Single-drug 
resistance is defined as resistance to only one antituberculous agent. 
MDR-TB, or multidrug-resistant TB, is a specific form of drug-resistant TB. It occurs when 
the TB bacteria are resistant to at least isoniazid and rifampicin, the two most powerful anti-
TB drugs. XDR-TB is an MDR TB strain that is resistant to any fluoroquinolone, and at least 
one of three injectable second-line drugs (capreomycin, kanamycin or amikacin). 
Traditionally, patients with drug-resistant tuberculosis are classified as having primary or 
acquired drug resistance on the basis of a history of previous treatment. WHO criteria define 
acquired drug resistance as the isolation of drug-resistant M. tuberculosis from a patient with 
a record of previous treatment for 1 month, and primary drug resistance as the isolation of a 
drug-resistant strain from a patient without a history of previous treatment. 
The classification of drug resistance as primary or acquired is used as an indicator of the 
efficiency of national tuberculosis programs and in the adjustment and development of 
these programs. The rate of primary drug resistance is interpreted as an epidemiological 
indicator for long-term surveillance of the quality of tuberculosis treatment in the 
community. The rate of acquired drug resistance reflects the efficacy of management of 
individual patients. 
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5. Molecular mechanisms of drug resistance 
As a consequence of the increase in DR TB and the relatively restricted number of 
therapeutic agents, there has been a renewed effort during the 2 past decades to define the 
molecular basis of drug resistance in MTB. 
MTB acquires drug resistance by antibiotic selection of mutations that occur randomly at 
chromosomal loci. No plasmids or transposable elements (horizontal gene transfer) are 
involved in this process. Individual nucleotide changes (point mutations) confer resistance 
to single drugs, and the stepwise accumulation of these mutations leads to MDR TB. drug 
resistance strains emerge when chemotherapy is intermittent or otherwise inadequate 
(Ducati, 2006; Zhang and Yew, 2009). 
5.1 First line drugs  
First-line drugs are mainly bactericidal and combine a high degree of efficacy with a relative 
toxicity to the patient during treatment. 
Currently, a five-drug regimen is used consisting of INH, RIF, SM, PZA and EMB. 
Resistance to first line anti-TB drugs has been linked to mutations in at least 10 genes; katG, 
inhA, ahpC, kasA and ndh for INH resistance; rpoB for RIF resistance, embB for EMB 
resistance, pncA for PZA resistance and rpsL and rrs for STR resistance. 
5.1.1 Isoniazid 
katG gene alterations. INH or isonicotinic acid hydrazide, was synthesized in the early 
1900s but its anti-TB action was first detected in 1951 (Heym, 1999; Slayden and Barry, 2000; 
Rattan, 1998). INH enters the cell as a prodrug that is activated by a catalase peroxidase 
encoded by katG. The peroxidase activity of the enzyme is necessary to activate INH to a 
toxic substance in the bacterial cell (Zhang, 1992). This toxic substance subsequently affects 
intracellular targets such as mycolic acid biosynthesis which are an important component of 
the cell wall. A lack of mycolic acid synthesis eventually results in loss of cellular integrity 
and the bacteria die (Barry, 1998). Middlebrook et al. (1954) initially demonstrated that a loss 
of catalase activity can result in INH resistance. Subsequently, genetic studies demonstrated 
that transformation of INH-resistant Mycobacterium smegmatis and M. tuberculosis strains 
with a functional katG gene restored INH susceptibility and that katG deletions give rise to 
INH resistance (Zhang, 1992; Zhang, 1993). However, mutations in this gene are more 
frequent than deletions in clinical isolates and these can lower the activity of the enzyme. 
Most mutations are found between codons 138 and 328 with the most commonly observed 
gene alteration being at codon 315 of the katG gene (Slayden and Barry, 2000). The Ser315Thr 
substitution is estimated to occur in 30–60% of INH resistant isolates (Ramaswamy and 
Musser, 1998; Musser, 1996; Slayden and Barry, 2000). The katG 463 (CGG-CTG / Arg-Leu) 
amino acid substitution is the most common polymorphism found in the katG gene and is 
not associated with INH resistance. 
Resistance to INH could be also due to mutations in the promoter region of the ahpC gene. 
Indeed, it has been observed that a loss of katG activity due to the S315T amino acid 
substitution is often accompanied by an increase in expression of an alkyl hydroperoxide 
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reductase (ahpC) protein that is capable of detoxifying damaging organic peroxides 
(Sherman, 1996). Five different nucleotide alterations have been identified in the promoter 
region of the ahpC gene, which lead to over expression of ahpC and INH resistance 
(Ramaswamy and Musser, 1998). AhpC overexpression exerts a detoxifying effect on organic 
peroxides within the cell and protects the bacteria against oxidative damage but does not 
provide protection against INH. KatG expression can also be up regulated under conditions 
of oxidative stress. The correlation between polymorphic sites in the ahpC regulatory region 
with INH resistance in M. tuberculosis requires further examination. 
inhA gene alterations. One of the targets for activated INH is the protein encoded by the 
inhA locus. InhA is an enoyl–acyl carrier protein (ACP) reductase which is proposed to be 
the primary target for resistance to INH and ethionamide (ETH) (Banerjee, 1994). ETH, a 
second line drug, is a structural analogue of INH that is also thought to inhibit mycolic acid 
biosynthesis and several studies have suggested that low-level INH resistance is correlated 
with resistance to ETH. Activated INH binds to the InhA-NADH complex to form a ternary 
complex that results in inhibition of mycolic acid biosynthesis. Six point mutations 
associated with INH resistance within the structural inhA gene have been identified 
(Ile16Thr, Ile21Thr, Ile21Val, Ile47Thr, Val78Ala and Ile95Pro) (Ramaswamy and Musser, 
1998; Basso and Blanchard, 1998). A Ser94Ala substitution results in a decreased binding 
affinity of inhA for NADH, resulting in mycolic acid synthesis inhibition. Although these 
mutations in the structural InhA gene are associated with INH resistance, it is not frequently 
reported in clinical isolates. InhA promoter mutations are more frequently seen and are 
present at positions -24(GT), -16(A-G), or -8(T-G/A) and -15(C-T). These promoter 
mutations result in over expression of inhA leading to low level INH resistance. To date 
approximately 70–80% of INH resistance in clinical isolates of M. tuberculosis can be 
attributed to mutations in the katG and inhA genes (Ramaswamy and Musser, 1998).  
kasA gene alterations. There seems to be considerable contreverse within the literature as to 
the role of kasA as a possible target for INH resistance (Sherman, 1996). This gene encodes a 
β-ketoacyl-ACP synthase involved in the synthesis of mycolic acids. Mutations have been 
described in this gene that confer low levels of INH resistance. Genotypic analysis of the 
kasA gene reveals 4 different amino acid substitutions involving codon 66 (GAT-AAT), 
codon 269 (GGT-AGT), codon 312 (GGC-AGC) and codon 413 (TTC-TTA) (Ramaswamy and 
Musser, 1998; Mdluli, 1998). However, similar mutations were also found in INH 
susceptible isolates (Lee, 1999; Piatek, 2000). Nevertheless, the possibility of kasA 
constituting an additional resistance mechanism should not be completely excluded. 
Ndh gene alterations. In 1998 another mechanism for INH resistance in M. smegmatis was 
described by Miesel et al. (1998). The ndh gene encodes NADH dehydrogenase that is bound 
to the active site of inhA to form the ternary complex with activated INH. Structural studies 
have shown that a reactive form of INH attacks the NAD(H) co-factor and generates a 
covalent INH-NAD adduct. Mutations in the ndh gene, encoding NADH dehydrogenase, 
cause defects in the enzymatic activity. Thus, defects in the oxidation of NADH to NAD 
result in NADH accumulation and NAD depletion (Lee, 2001). These high levels of NADH 
can then inhibit the binding of the INH-NAD adduct to the active site of the InhA enzyme 
(Rozwarski, 1998; Miesel, 1998). Prominent point mutations in the ndh gene at codons 110 
and 268 (T110A and R268H) were detected in 9.5% of INH resistant samples. These similar 
mutations were not detected in the INH susceptible group (Lee, 2001). 
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5.1.2 Rifampicin 
Rifampicin (RIF) is a major compound of anti-tuberculosis chemotherapy. A resistance to RIF 
is rarely found without associated resistance to other tuberculostatics. RIF resistance is a good 
marker for MDR-TB. Moreover, RIF resistance is a good predictor of poor treatment outcome. 
The mode of action of RIF is based on the inhibition of the elongation of transcripts by RNA 
polymerase in MTB, by covalent binding to the Beta sub-unit of RNA polymerase, thus leading 
to cell death. The RNA polymerase Beta sub-unit is encoded by the rpoB gene. RIF resistance is 
associated with a hotspot (codon 507 to 533) core region called RRDR, for “rifampicine 
resistance determining region” (81 bp) of the rpoB gene. More than 95% of RIFR M. tuberculosis 
has a mutation in this specific region (Telenti, 1993; Telenti, 1997). 
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Fig. 1. Mutations of the rpoB gene associated with a resistance to rifampicin in M. tuberculosis 
Resistance to RIF occurs at a frequency of 1 out of 107 to 108 bacterial cells. Most RIF-
resistant strains show one mutation in the gene. Two to four mutations are rarely reported 
(Mani, 2001; Sekiguchi, 2007). The most prevalent mutations (81%) affect codons 531 and 526 
and usually lead to a high level of phenotypical resistance (MIC > 64 µg/ml) as well as cross 
resistance to other rifamycins (Riska, 2000; Zhang, 2005). Mutations at codons 511, 516, 518 
and 522 result in a low-level resistance to RIF and rifapentine; and some susceptibility to 
rifabutin (Zhang, 2005). 
At the same time, mutations in this hotspot region seem to confer low phenotypical 
resistance (deletion of codon 508-509, mutation at 515) (Taniguchi, 1996) or variable 
resistance (L533P) (Kim, 1997), which could lead to an overly hasty interpretation of 
resistance. The latest observations of Asian strains suggest a geographic variability that can 
influence the accuracy of genotypic tests (Riska, 2000). 
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Silent mutations (Leu511 and Leu521) have been reported in resistant strains. Interestingly, 
the L511L mutation is always associated with other mutations that confer resistance 
(Siddiqi, 2002). In rare cases, double mutations appear to have an additive effect on the 
degree of resistance. The role of mutations, combined with those known to confer resistance, 
is uncertain, as in the case of S509R described with H526R (Sekiguchi, 2007). 
Finally, less than 5% of resistant strains do not show a mutation in the rpoB resistance region 
(Riska, 2000; Mani, 2001). Rare loci found outside the hotspot region of rpoB are associated 
with resistance without associated mutation known for conferring resistance (Taniguchi, 
1996; Fang, 1999; Schilke, 1999; Yuen, 1999; Heep, 2001; Zhang, 2005; Rigouts, 2007; 
Prammananan, 2008). 
Mutated strains in Val146Phe (Heep, 2001; Rigouts, 2007; Prammananan, 2008) show a low-
level resistance (MIC 4 µg/ml) (Rigouts, 2007). The Ala381Val mutation (Taniguchi, 1996) is 
described on a strain of MIC 200, with no other mutation on the rpoB gene.  
Most susceptible strains show no mutation, except for a few: seven susceptible Japanese 
strains are mutated in TCG Ser 450 Leu TTG, ATG Met511 Val GTG, CTG Leu 521 Pro CCG, 
CTG Leu 533 Pro CCG, GCC Ala 679 Ser TCC (two strains) and CGC Arg 687 Pro CCC 
(Taniguchi, 1996; Yang, 1998). The CTG Leu 533 Pro CCG mutation has been shown on two 
strains of low-level resistance (MIC 12.5 µg/ml) and on a strain that is susceptible according 
to phenotypic tests, yet clinically resistant (Riska, 2000). Other studies describe some 
sensitive strains with mutations as Ser 450 Leu (Sekiguchi, 2007), Leu 511 Arg or Ser 512 Thr 
(Moghazeh, 1996) or Gln CAA 513 Gln CAG (Kim, 1997). Genotypic detections would 
therefore be more sensitive in certain circumstances. 
5.1.3 Streptomycin 
SM is an aminocyclitol antibiotic that is one of the first drug used to treat TB, SM binds to 
16S rRNA, inhibits translational initiation and detrimentally affects translation fidelity. 
Mutations associated with SM resistance in MTB have been identified mainly in rpsL gene 
encoding ribosomal protein S12 and in the 16S rRNA gene (rrs) in 65–67% of STR resistant 
isolates (Ramaswamy and Musser, 1998).  
In the rrs gene a C-T transition at positions 491, 512 and 516, and a A-C/T transversion at 
position 513 were observed in the highly conserved 530 loop. The 530 loop region is part of 
the aminoacyl–tRNA binding site and is involved in the decoding process (Carter, 2000). 
The C-T transition at codon 491 is not responsible for resistance to STR as it occurs in both 
STR resistant and susceptible isolates but is strongly associated with the global spread of M. 
tuberculosis with a Western Cape F11 genotype (van Rie, 2001; Victor, 2001). Other mutations 
in the 915 loop [903 (C-A/G) and 904 (A-G)] have also been reported to have an association 
with STR resistance (Carter, 2000). Mutations in the rpsL gene at codon 43 (AAG-
AGG/ACG) (Lys-Arg/Thr) and codon 88 (AAGAGG/ CAG) (Lys-Arg/Gln) are associated 
with STR resistance. MIC analysis of STR resistant isolates indicate that amino acid 
replacements in the rpsL genes correlate with a high level of resistance, whereas mutations 
in the rrs gene correlate with an intermediate level of resistance (Cooksey, 1996; Meier, 
1996). In addition, it has been suggested that low levels of STR resistance are also associated 
with altered cell permeability or rare mutations which lie outside of the rrs and rpsL genes. 
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5.1.4 Pyrazinamide  
Pyrazinamide (PZA) is a structural analog of nicotinamide that is used as a first –line TB 
drug. PZA kills semi-dormant tubercle bacilli under acidic conditions. PZA targets an 
enzyme involved in fatty-acid synthesis and is responsible for killing persistent tubercle 
bacilli in the initial intensive phase of chemotherapy (Somoskovi, 2001). However, during 
the first two days of treatment, PZA has no bactericidal activity against rapidly growing 
bacilli (Zhang and Mitchison, 2003). PZA on the other hand has effective sterilizing 
activity and shortens the chemotherapeutic regiment from 12 to 6 months. PZA is a 
prodrug which is converted to its active form, pyrazinoic acid (POA) by the 
pyrazinamidase (PZase) encoded by pncA. The activity of PZA is highly specific for M. 
tuberculosis, as it has no effect on other mycobacteria. Mycobacterium bovis is naturally 
resistant to PZA due to a unique C-G point mutation in codon 169 of the pncA gene. PZA 
is only active against M. tuberculosis at acidic pH where POA accumulates in the 
cytoplasm due to an ineffective efflux pump. Accumulation of POA results in the 
lowering of intracellular pH to a level that inactivates a vital fatty acid synthase 
(Zimhony, 2004). Cloning and characterization of the M. tuberculosis pncA gene by Scorpio 
et al. (1997) showed that some pncA mutations conferred PZA resistance. Various pncA 
mutations have been identified in more than 70% of PZA resistant clinical isolates 
scattered throughout the pncA gene but thus far no mutational hot spot has been 
identified (Scorpio and Zhang, 1996; Sreevatsan, 1997b; Scorpio, 1997). PZA susceptibility 
testing is not done routinely in many countries due to technical difficulties. Thus the 
extent of PZA resistance globally is largely unknown. PZA resistant isolates had diverse 
nucleotide changes scattered throughout the pncA gene. However, PZA resistant isolates 
without pncA mutations were also observed suggesting that another mechanism may be 
involved in conferring PZA resistance in these isolates. In addition, not all mutations (e.g. 
Thr114Met) were associated with PZA resistance. In summary, the complexity of PZA 
resistance makes the development of molecular methods for rapid diagnosis difficult. 
5.1.5 Ethambutol 
Ethambutol (EMB) is a very specific and effective drug that is used in combination with INH 
to treat M. tuberculosis infection (Ramaswamy and Musser, 1998). EMB inhibits an arabinosyl 
transferase (embB) involved in cell wall biosynthesis (Takayama and Kilburn, 1989).Three 
genes designated embC, A and B (Telenti, 1997) encode homologous arabinosyl transferase 
enzymes involved in EMB resistance. Various studies have identified five mutations in 
codon 306 of embB gene [(ATG-GTG), (ATG-CTG), (ATG-ATA), (ATG-ATC) and (ATG-
ATT)] which result in three different amino acid substitutions (Val, Leu and Ile) in EMB-
resistant isolates (Lee, 2002; Sreevatsan, 1997c; Mokrousov, 2002b; Ramaswamy, 2000). 
These five mutations are associated with 70–90% of all EMB resistant isolates (Ramaswamy 
and Musser, 1998). Missense mutations were identified in three additional codons: 
Phe285leu, Phe330Val and Thr630Ile in EMB resistant isolates. MIC’s were generally higher 
for strains with Met306Leu, Met306Val, and Phe330Val and Thr630Ile substitutions than 
those organisms with Met306Ile substitutions. Mutations outside of codon 306 are present 
but quite rare. However a number of EMB phenotypic resistant isolates (about 30%) still lack 
an identified mutation in embB. There is therefore a need to fully understand the mechanism 
of EMB resistance in clinical isolates. 
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5.2 Second line drugs  
5.2.1 Fluoroquinolones 
Ciproflaxin (CIP) and ofloxacin (OFL) are the two fluoroquinolones (FQs) used as second-
line drugs in MDR-TB treatment (WHO, 2001). These FQs are bactericidal against MTB. 
Their target is the DNA gyrase, an ATP-dependent type II DNA topoisomerase that 
catalyses negative supercoiling of DNA. DNA gyrase is a tetrameric protein composed of 
two A and two B subunits encoded by the gyrA and gyrB genes, respectively. FQs bing to 
gyrase and inhibit supercoiling of DNA, thereby disrupting cellular processes dependent on 
DNA topology (Ramaswamy and Musser, 1998). 
The quinolone resistance-determining region (QRDR) is a conserved region in the gyrA 
(320bp) and gyrB (375bp) genes (Ginsburg, 2003) which is the point of interaction of FQ and 
gyrase (Ginsburg, 2003). Missense mutations in codon 90, 91, and 94 of gyrA are associated 
with resistance to FQs (Takiff, 1994; Xu, 1996). A 16-fold increase in resistance was observed 
for isolates with a Ala90Val substitution, a 30-fold increase for Asp94Asn or His94Tyr and a 
60-fold increase for Asp94Gly (Xu, 1996). A polymorphism at gyrA codon 95 is not 
associated with FQ resistance, and is used, with the katG463 polymorphism, to classify M. 
tuberculosis into 3 phylogenetic groups (Sreevatsan, 1997a). 
5.2.2 Ethionamide 
Ethionamide (ETH) is a derivative of isonicotinic acid with potent activity against MTB and 
other mycobacteria. Like INH, ETH is also thought to be a prodrug that is activated by 
bacterial metabolism. The activated drug then disrupts cell wall biosynthesis by inhibiting 
mycolic acid synthesis. Mutations in the promoter of the inhA gene are associated with 
resistance to INH and ETH (Morlock, 2003). EthA catalyses a two step activation of ETH and 
gene alterations leading to reduced EthA activity lead to ETH resistance (Engohang- Ndong, 
2004; Morlock, 2003; Vannelli, 2002). The expression of ethA is under the control of the 
neighbouring ethR gene encoding a repressor. EthR negatively regulates the expression of 
ethA, by binding upstream of ethA to suppress ethA expression (Engohang-Ndong, 2004). 
5.2.3 Kanamycine and amykacine 
KAN and AMY are aminoglycoside antibiotics that inhibits protein synthesis by inhibiting 
the normal function of ribosomes (Taniguchi, 1997; Ramaswamy and Musser, 1998). These 
drugs are used as second line anti-TB agents. Nucleotide substitutions in the region of rrs 
especially at position 1400 (between the rrs gene and 23S rRNA gene) are a major cause of 
resistance to KAN and AMY in M.tuberculosis. It seems that nucleotide substitutions at rrs 
position 1400 is implicated in high-level resistance to KAN and AMY (Taniguchi, 1997). 
5.2.4 D-Cycloserine 
D-cycloserine (DCS) is a cyclic analog of D-alanine which is one of the central molecules of 
the cross linking step of peptidoglycan assembly (Ramaswamy and Musser, 1998; Feng and 
Barletta, 2003). DCS inhibits cell wall synthesis by competing with D-Alanine for the 
enzymes D-alanyl-D-alanine synthetase (Ddl) and D-alanine racemase (Alr) and also 
inhibiting the synthesis of these proteins. Overexpression of alr causes DCS resistance. The 
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G→T transversion in the alr promoter may lead to the overexpression of alr (Feng and 
Barletta, 2003; Ramaswamy and Musser, 1998). 
5.2.5 Peptides 
Viomycin (VIO) and capreomycin (CAP) are basic peptide antibiotics that inhibit 
prokaryotic protein synthesis and have shown that resistance to VIO in M. smegmatis is 
caused by alterations in the 30S or 50S ribosomal subunits (Taniguchi, 1997). Mutations in 
the rrs gene that encodes the 16S rRNA is associated with resistance to VIO and CAP, 
specifically a G→A or G→T nucleotide change at codon 1473 (Taniguchi, 1997). 
6. Availables tests for tuberculosis diagnosis 
6.1 History 
Since the 1880s with the development of the sputum smear microscopy, the most commonly 
used for TB diagnostic, several new and established methods were developed and 
implemented in many laboratory services worldwide to enhance MTB diagnosis and 
tuberculosis management. 
The sputum smear microscopy has remained largely unchanged and is often described as a 
simple technology. However, it requires a high level of training and diligence. 
Because microscopy is both cumbersome to implement and inherently insensitive, many 
patients remain undiagnosed and many non-TB patients are incorrectly treated with TB 
drugs on the basis of clinical suspicion alone. In endemic countries, simply obtaining an 
accurate diagnosis often takes weeks or months from the time a patient first visits a health 
centre. This delay prevents prompt treatment of TB and leads to continued disease 
transmission, at substantial cost to the individual and at huge cost to society. 
Mounting drug resistance, including MDR-TB and extensively drug-resistant (XDR) TB, 
coupled with a growing number of people co-infected with TB and HIV, have highlighted 
the urgent need for more accurate and rapid diagnostic tests. Many patients are never 
diagnosed and contribute to the astonishing number of yearly deaths from TB worldwide. 
The global control of tuberculosis remains a challenge from the standpoint of diagnosis, 
detection of drug resistance, and treatment. Thus, there recently has been a marked increase 
in the development and testing of novel assays designed to detect MTB complex and/or 
MDR MTB based either on conventional techniques or on molecular approaches. The Figure 
2 summarise the main techniques used and under development for TB diagnosis. 
Recently, the WHO has endorsed some of these novel methods, and they have been made 
available at discounted prices for procurement by the public health sector of high-burden 
countries. In addition, international and national laboratory partners and donors are 
currently evaluating other new diagnostics that will allow further and more rapid testing in 
point-of-care settings. While some techniques are simple, others have complex requirements, 
and therefore, it is important to carefully determine how to link these new tests and 
incorporate them within a country's national diagnostic algorithm. Finally, the successful 
implementation of these methods is dependent on key partnerships in the international 
laboratory community and ensuring that adequate quality assurance programs are inherent 
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in each country's laboratory network. Moreover, it’s widely accepted that if left untreated, 
each person with active TB infects an average of 10 to 15 people each year. Interrupting 
disease transmission will require early and accurate detection paired with appropriate 
treatment. 
 
Fig. 2. Tuberculosis product deliverables 2007 2016 
6.2 Conventional tests 
Tuberculosis is generally diagnosed by traditional laboratory procedures, including 
microscopic examination of samples for the presence of acid-fast bacilli (AFB) and/ or 
isolation by culture followed by identification using biochemical tets. 
6.2.1 Microscopic examination 
The etiological diagnosis of tuberculosis is based on the appearance of bacilli in clinical 
samples (sputum). Direct sample examination according to Ziehl-Neelsen staining is used to 
screen for positive bacilli results. For pulmonary tuberculosis, direct examination of sputum 
is fast and reveals the quantity of acid-fast bacillus, and thus the risk of contagiousness. 
However, direct examination has a low susceptibility of 22% to 78% and can only detect a 
concentration of 103 bacilli / ml or more in the sample. In addition, it is not species specific. 
As a result, false-positives occur, particularly in heavily colonized samples from children 
patients with other chronic pulmonary infections and paucibacillary cases common among 
HIV-infected individuals. Nevertheless, many countries use direct examination of samples 
as a quick test for diagnosing tuberculosis. Early diagnosis can improve patient survival and 
reduces the spread of the M. tuberculosis strain.  
Because of the limitations of conventional light microscopy using stains such as Ziehl-Neelsen, 
fluorochrome stains such as auramine were introduced that improve the sensitivity of the test 
and take less time to perform. However, fluorescence microscopy has the limitations of 
requiring a fluorescent microscope, a dark room, and an expensive light source. 
Mercury vapor light sources used for this type of microscopy can also pose a hazard if bulbs 
are broken. To overcome these limitations, light emitting diode (LED) microscopy was 
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developed. This type of microscopy uses LED technology as a light source but still allows 
for the advantages of using a fluorescent stain while eliminating most of the disadvantages 
of fluorescent microscopy. LED microscopy is more sensitive and equally specific, compared 
with either conventional light or fluorescent microscopy. 
The World Health Organization (WHO) recommends that conventional fluorescence 
microscopy could be replaced by LED microscopy, and that LED microscopy should be 
‘‘phased in as an alternative for conventional light microscopy’’. 
6.2.2 Culture  
It’s widely accepted that TB culture is substantially more sensitive, but is very slow, and 
results often do not get back to the health care workers until too late to be clinically useful. 
Culture is needed to screen for bacilli either on solid (Lowenstein-Jensen [LJ]) or liquid 
(mycobacterial growth indicator tube [MGIT 960]) media.  
In Morocco, as it’s the case in many countries worldwide, culture on solid media using 
Lowenstein-Jensen is the main technique used to detect TB in samples. The culture-
dependent laboratory procedures may take 4 to 6 weeks to have MTB cultures both for TB 
diagnosis and for further analyses e.g. Drug susceptibility testing (Eing, 1998).  
The liquid culture (LC) gives an alternative opportunity to enhance TB diagnosis by 
conventional techniques. In fact, LC is significantly faster: the average time-to-growth 
detection with liquid culture is 10 to 14 days. Controlled trials have demonstrated that the 
performance of liquid media culture (LMC) is superior to that of solid media culture for 
diagnosis of MTB (Srisuwanvilai, 2008), but there is limited evidence about its performance 
in resource-limited settings.  
TB culture on liquid media uses the Mycobacterium Growth Indicator Tube (MGIT). The 
MGIT is a commercial liquid culture system and the leading rapid culture method in the 
developed world. MGIT is manufactured in unbreakable plastic tubes containing enriched 
culture media. At the bottom of the tube is a silicone plug containing chemicals that become 
fluorescent when bacteria consume oxygen during the process of growth, making detection 
possible using either manual or automated systems. MGIT was approved by the World 
Health Organisation in 2007 and is already in use in high income countries and in the 
private sector. Its implementation in endemic countries is ongoing. 
The roll-out of MGIT for case detection is especially important for patients with low 
numbers of TB bacteria in their sputum, such as children and individuals infected with HIV. 
6.3 Molecular tests for diagnosis and identification of mycobacterial species 
Because traditional techniques have several limitations, considerable progress has recently 
been made in developing novel approaches and tools, especially molecular methods 
(commercial and 'in-house'), for direct detection and identification of M. tuberculosis in 
clinical specimens within a single day after sputum collection. The potential advantages of 
molecular assays are the ability to (1) design assays that are highly sensitive and specific; (2) 
manufacture some assays in large quantities, allowing for decreased cost and ease of 
standardization in field use; (3) yield rapid results; and (4) be used more widely, because 
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they require less training and infrastructure than do conventional mycobacterial cultures 
and AST. 
These potential advantages must be weighed against the disadvantages of these assays, 
some of which are common to all molecular techniques and others specific to particular 
assays. Among the disadvantages of molecular assays are (1) a need for laboratory 
infrastructure that can accommodate molecular testing; (2) cost; (3) a continued need of 
cultures for AST; and (4) most work better with smear-positive than with smear-negative 
specimens. 
These methods, based on nucleic acid amplification (NAA) of different targets, aim to 
identify the M. tuberculosis complex, and eventually drug resistant strains. In general, 
commercial methods are recommended since they have a better level of standardization, 
reproducibility and automation. Although some aspects such as cost-efficiency and the 
appropriate setting for the implementation of these techniques are not yet well established, 
organizations such as the WHO are strongly supporting the implementation and universal 
use of these new molecular methods (Moure, 2010).  
The available molecular methods for direct detection of MTB from clinical samples include 
in house polymerase chain (PCR) using essentially IS6110, hsp65 and 16SrRNA as target. 
Two Commercial nucleic acid amplification ( NAA) tests for MTB detection in clinical 
specimens are available: the Enhanced MTB Direct Test (E-MTD), the Amplicor MTB test 
and its automated version the Cobas Amplicor MTB test, the BDProbe tec ET test, 
GeneXpert MTB/RIF Assay and the INNO-LiPA-Rif (Innogenetics, Ghent, Belgium). 
6.3.1 Classical PCR using essentially IS6110, Hsp 65 and 16SrRNA as targets 
The polymerase chain reaction (PCR) has been most widely used for the detection of M. 
tuberculosis in clinical specimens including sputum, blood, bone marrow, and biopsy 
samples. 
The MTB Complex-specific insertion sequence 6110 is commonly used as a target for 
detecting MTB. The overall sensitivity and specificity of the assay range from 84.2-100% and 
83-100%, respectively, for respiratory specimens (Shamputa, 2004).  
The performance of the in house IS6110 PCR in direct detection of MTB on sputum has been 
evaluated in Morocco and showed promising results (under publication). 
However, in non-respiratory samples, lower sensitivities were recorded in most studies with 
the exception of successful detection in pleural biopsy specimens in one study, and even in 
blood samples in another study. 
The main advantage of the IS6110 targeted NAATs is the fact that most MTBC isolates carry 
more than five copies of this transposon, thereby increasing the sensitivity of the test. 
However, in some Asian regions MTBC isolates with no or few IS6110 copies are more 
prevalent. 
The 16S rRNA and the Hsp65 genes have also been used to detect MTBC in respiratory and 
non-respiratory clinical specimens with high sensitivity and specificity values. In Morocco, 
the use of hsp656 gene as a PCR target was evaluated as a direct method for the diagnosis of 
MTB in 70 clinical specimens (62 sputum, 6 cerebrospinal fluids, and 2 biopsies). Results 
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showed a sensitivity of 81.13 % with specificity of 88, 24 % as compared with conventional 
techniques. Moreover, the positive and negative predictive values were 95.56 %, 60% 
respectively (Zakham, 2011). 
6.3.2 The amplicor MTB test and its automated version the Cobas Amplicor MTB test 
The amplicor test is based on the PCR. In this assay, mycobacterial DNA is amplified with 
genus-specific primers formulated on the basis of the 16S rRNA gene. After denaturation, 
the amplicons are added to a microtiter plate containing a bound, M tuberculosis complex-
specific oligonucleotide probe. An avidin-horseradish peroxidase conjugate then binds to 
the bound, biotin labelled amplicons. The conjugate then reacts with with peroxide and 
3,39,5,59-tetramethylbenzidine in dimethylformamide to form a color complex. The 
results are measured with a photometer (D’Amato, 1995; Soini and Musser, 2001; 
Ozkutuk, 2006).  
The Amplicor results are available in 6.5 h. An automated version of this test is available 
(Cobas Amplicor).The overall sensitivity of the Amplicor test (compared with culture) for 
respiratory specimens is 79.4 –91.9%, the specificity is 99.6 –99.8%. However, the sensitivity 
for smear negative specimens is somewhat lower, 40.0–73.1% (Bergmann, 1996; Stauffer, 
1995; Tevere, 1996; Eing, 1998). Therefore, the Amplicor test has been approved by the Food 
and Drug Administration (FDA) only for direct detection of M. tuberculosis in AFB smear-
positive respiratory specimens. Chin et al. (Chin, 1995) reported that the sensitivity of the 
Amplicor test was similar to that of culture (58% vs 56%) for detecting M. tuberculosis from 
respiratory specimens when the clinical case definition of TB was used as the reference 
standard. However, Al Zahrani et al. (2000) reported that although the Amplicor test had 
excellent specificity (100%), it was less sensitive than culture (42% vs 73%) for diagnosis of 
minimal active pulmonary TB (patients suspected of having TB but without spontaneous 
sputum or with AFB-negative smears). 
6.3.3 Enhanced MTB direct test (E-MTD) 
The E-MTD test is based on the transcription-mediated amplification system developed by 
Kwoh et al. (1989). In this assay, rRNA is released from the target cells by sonication, and a 
promoter-primer binds to the rRNA target. Reverse transcriptase is then used to copy rRNA to 
a cDNA-RNA hybrid. The initial RNA strand is degraded, and a second primer binds to the 
cDNA and is extended, leading to the formation of double-stranded cDNA, which is then 
transcribed by DNA-directed RNA polymerase to produce more rRNA molecules. The new 
transcripts serve as templates for reverse transcription and further amplification. The RNA 
amplicons are detected with an acridinium ester-labeled DNA probe in a solution 
hybridization assay. Importantly, the amplification procedure is isothermal and the reaction is 
performed in a single tube, which helps to reduce carryover contamination. After standard 
decontamination of the clinical specimen, the E-MTD test can be completed in 3.5 h. 
The E-MTD test is FDA-approved for detection of M. tuberculosis in both AFB smear-positive 
and smear-negative specimens. The overall sensitivity (compared with culture) for 
respiratory specimens is 90.9 –95.2%, the specificity 98.8–100% (Bergmann, 1999; Gamboa, 
1998; Smith, 1999).The performance of the E-MTD and the Cobas Amplicor is the same 
(Scarparo, 2000). However, it was noted that although the turnaround time is shorter for the 
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E-MTD test, the Amplicor test can be fully automated and has an internal control for 
monitoring amplification inhibitors. 
6.3.4 BDProbeTec ET test 
The BDProbeTec ET system allows amplification and detection of M. tuberculosis complex 
(MTBC) DNA in 1 h and simultaneously detects the presence of inhibitors as well. The target 
of the BDProbeTec ET system is a 95-bp region of IS6110, a highly specific insertion element 
in the MTBC DNA where it is present in multiple copies. Nucleic acid amplification is 
isothermal and is based on homogeneous strand displacement amplification (SDA) (Spargo, 
1993), while detection is based on real-time fluorescent energy transfer (Little, 1999). An 
internal amplification control (IAC) is run with each sample to confirm the validity of the 
amplification reaction and to identify potential inhibitory factors from the processed 
specimen. 
Of the published studies on the BDProbeTec system, sensitivities and specificities for 
respiratory samples were ranging from 82.7% to 100% and from 96.5% to 99.8% respectively 
(Mazzarelli, 2003). The extrapulmonary specimens represent a major diagnostic problem, 
mainly as they are often paucibacillary and at times contain inhibitors. With such samples, 
the resolved sensitivity of the BDProbeTec ET system is lower (77.8%) than with pulmonary 
specimens (91.5%), but nevertheless higher than with microscopy (63.1%) (Mazzarelli, 2003; 
Cho, 2007). 
Other tests, Xpert MTB/RIF Assay (Cepheid) and INNO-LiPA-Rif (Innogenetics, Ghent, 
Belgium), used both for TB diagnosis and TB drug resistance screening will be discussed in 
later. 
7. Diagnosis of drug resistant tuberculosis 
7.1 Conventional tests 
7.1.1 Microscopic Observation Drug Susceptibility (MODS) assay 
The MODS assay is a broth microtiter method designed to detect M. tuberculosis complex 
and to detect resistance to isoniazid and rifampin (Moore, 2006; Mello, 2007; Ha, 2010). The 
method uses standard microtiter plates and other materials that are readily available in 
larger diagnostic laboratories. The method is straightforward: microtiter plates are prepared 
that contain Middlebrook 7H9 broth medium, growth supplements, and antimicrobial 
agents to prevent overgrowth of bacterial contaminants. Anti-TB drugs, at different 
concentrations, are added to some of the wells (Wilson, 2011).  
The performance characteristics of the MODS assay were summarized in a recent meta-
analysis. For detecting lowlevel resistance to isoniazid the pooled sensitivity of the assay is 
97.7% and specificity is 95.8%. For detecting high-level isoniazid resistance, the sensitivity 
decreases to 90.0%, but the specificity increases to 98.6%. For detection of rifampin 
resistance, the pooled sensitivity is 98.0% and the specificity is 99.4%. This meta-analysis did 
not summarize the ability of the assay to identify the presence of M. tuberculosis in sputum 
specimens (Ha, 2010; Minion, 2010). 
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The published sensitivity of the assay varies from 87.4% to 97.8%, although the assay was 
compared with different gold standards in these studies. The contamination rate for the 
MODS assay, although lower than that of solid media, is higher than that of liquid media 
(Minion, 2010). 
7.1.2 Drug susceptibility testing 
The standard methods using the Lowenstein-Jensen (LJ) or agar proportion method (PM) 
(Canetti 1963, 1969, Kent & Kubica 1985) and the radiometric method in BACTEC TB-460 
system (Becton-Dickinson) (Roberts 1983) are the current standard methods recommended 
to perform susceptibility testing of M. tuberculosis. The absolute concentration method is also 
commonly used on account of its technical simplicity for inoculums preparation and for 
reading results. 
In order to shorten the turnaround time and make it more convenient for case management, 
numerous new techniques have appeared, aiming to detect growth inhibition as early as 
possible. The most commonly used systems are detection of CO2 production, such as 
BACTEC 460 (Hawkins, 1991) or MB/Bact (Diaz-Infantes, 2000), and oxygen consumption, 
such as Mycobacteria Growth Indicator Tube (Bemer, 2002); there are others in 
developmental stage. However, many of those new techniques are difficult to implement in 
the developing countries where they are needed the most, because of high costs, technical 
complexity and absence of appropriately trained human resources.  
7.1.3 DST on liquid medium 
MGIT can also be used to perform drug susceptibility testing (DST), which is done by 
comparing the growth of mycobacteria with and without the addition of drugs used to treat 
TB. The combined use of MGIT for both TB detection and DST can shave months off the 
conventional process of identifying multidrug-resistant (MDR) TB (Hanna, 1999; Rusch-
Gerdes, 1999). 
Despite having been developed over a decade ago, the advantages of MGIT for TB detection 
were not reaching most endemic settings for several reasons. This was primarily due to the 
cost of the test, the lack of a simple means to confirm the growth of M. tuberculosis species in 
positive tubes, and the lack of data demonstrating that the use of liquid culture was feasible 
in resource-constrained settings. FIND has partnered with BD to overcome these obstacles 
and introduce MGIT as a solution for case detection and DST in developing countries. 
7.1.4 Colorimetric assays 
A colorimetric method for detecting microbial growth in drug-resistant strains was 
described in 1998 and subsequently evaluated in a limited number of clinical trials (Martin, 
2005; Abate, 2004; Montoro, 2005). The assay is based on the observation that growing 
tubercle bacilli convert a yellow dye [3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium 
bromide or MTT] to a purple color that can be detected visually or by use of a 
spectrophotometer. In field trials, the method has been shown to have a high degree of 
concordance with conventional AST (Martin, 2005; Abate, 2004; Montoro, 2005). The method 
has been compared with a nitrate reduction assay and a resazurin assay for detecting 
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resistance to isoniazid, rifampin, ethambutol, and streptomycin; similar results were 
obtained for isoniazid and rifampin, but only the nitrate reduction assay showed a high 
level of concordance with all of the first-line drugs. Although these methods are 
conceptually straightforward, they are likely to be useful primarily in larger laboratories 
with the capacity to perform more complex assays (Montoro, 2005; Wilson, 2011). 
7.2 Molecular tests 
Several molecular detection methods for drug resistance are of great value; all these 
methods are based on the observation that resistance to anti-TB drugs develops through the 
sequential accumulation of mutations in mycobacterial genes targeted by different drugs. 
Mutations in specific codons can therefore be used to rapidly detect drug resistance, since 
drug susceptible samples lack the corresponding gene mutation. These Molecular methods 
are fast and reliable and can potentially reduce the diagnosis time from weeks to days, 
These methods include PCR-based sequencing, PCR-Restriction Fragment Length 
Polymorphism, PCR-Single Strand Conformation Polymorphism (PCR-SSCP), Heteroduplex 
Analysis, DNA Microarrays and Probe methods. Moreover, a commercially available DNA 
strip assay (Genotype MTBDR; Hain Lifescience, Nehren, Germany) for detection of 
mutations conferring resistance to Rifampin (RMP) and Isoniazid (INH) in clinical 
Mycobacterium tuberculosis isolates is now widely used. GeneXpert MTB/RIF Assay and the 
INNO-LiPA-Rif (Innogenetics, Ghent, Belgium), are two rapid assays for simultaneous 
detection of MTBC and determination of the rifampicin (RIF) resistance profile (a marker for 
multidrug resistance). 
7.2.1 PCR-based sequencing 
PCR-based sequencing is the main technique used to elucidate the genetic mechanisms of 
drug resistance in M. tuberculosis. It is the most direct and reliable method for studying 
mutations and allows for detection of both previously recognized and unrecognized 
mutations. Unfortunately, the method is not as readily applicable for routine 
identification of drug resistance mutations as it is for identification of mycobacterial 
species because many different genes may be involved, as is the case in INH resistance, or 
the mutations may be scattered in a large segment of the gene. This means that several 
sequencing reactions need to be performed for each isolate. However, for targets such as 
rpoB, where mutations associated with RIF resistance are concentrated in a very short 
segment of the gene, PCR-based sequencing is a useful technique (Soini, 2001; Johnson, 
2006; Kourout, 2009). 
A previous study was done in Morocco to characterize mutations in rpoB gene associated 
with rifampicin (RMP) resistance in 47 RMP-resistant and 147 RMP-susceptible clinical 
strains of Mycobacterium tuberculosis by DNA sequencing. RMP-resistant mutations were 
identified in 85% of RMP-resistant isolates. Sequence analysis identified 10 alleles, including 
two deletions not previously reported: 514-515 Δ (Phe-Met → Leu) and 519-520 Δ (Asn-Pro). 
Nucleotide changes at codons 531, 526 and 516 were the most prominent, accounting for 
74.4% of our RMP-resistant strains. These results demonstrate that DNA sequencing is an 
efficient tool for rapid detection of RMP resistance (Kourout, 2009). 
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7.2.2 Probe based hybridization methods 
DOT BLOT strategy 
It is a technique which can detect any known or newly described mutations and which can 
fulfil the criteria of accuracy, speed and simplicity. The hybridization with wild type probes 
can be used to efficiently screen for all mutations conferring drug resistance. The method 
includes: 
 PCR amplification for target genes 
 Confirmation of PCR amplification by gel electrophoresis 
 Blotting PCR product on a filter using dot blot apparatus 
 Labelling of probes for region of interest: the probes are 5’ end-labelled by 
phosphorylation with [∂32P]-ATP or 3’ end-labelled with digoxigenin by terminal 
transferase. 
 Dot Blot hybridization 
 Autoradiography. 
Although radioactive and non-radioactive detection procedures gave similar results, the 
radioactive procedure was favoured to empirically evaluate stringent hybridization washes 
during the development phase of this strategy. 
The dot –blot procedure may be specifically useful in countries with a high incidence of 
TBand where procedures such as automated DNA sequencing are not readily available. As 
the predictive value of any test is dependent on prevalence, a mutational screening strategy 
should initially focus on the mutations most frequently diagnosed in the geographic area 
studied. 
Codons 315 (KatG), 516,526 and 531 (rpoB), 43 (rpsL), 491,513 (rrs) and 306 (emb) are 
frequently altered in clinical isolates from many studies (Victor, 1999, Sabouni, 2008; 
Kourout, 2009; Chaoui, 2009). Such methods are needed to determine the most important 
mutations associated with drug resistance in different geographical regions, since it is 
known that drug resistant mutations may vary with the geographical origin of the sample. 
The wild type probe strategy is unable to provide a precise understanding of the different 
mutations occurring at a specific codon, however, it is known that 99% of mutations within 
these loci confer resistance and therefore the absence of a hybridization signal has been 
interpreted to directly reflect drug resistance. The application of specific mutant probes 
allows the identification or the confirmation of the nature of this mutational event. The 
method is reproducible, not technically demanding and it takes about two normal working 
days to obtain results. This technique could be adapted to amplify and detect drug resistant 
mutations directly from sputum samples or microscopy stained slides. 
7.2.3 Reverse line probe assay 
This approach involves a combination of DNA amplification and reverse-line blot 
hybridisation. This home made and low cost test was first developed to detect RIF resistant 
isolates (RIFO): in this test , the DNA of rpoB gene of MTB is amplified by PCR using specific 
primers. Then, the PCR products are hybridized to oligonucleotides on a DNA membrane, 
encoding the consecutive parts of of the rpoB gene sequence and the consecutive parts of of 
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the rpoB gene sequence with the most frequently occurring mutations in rifampicin-resistant 
strains. The rpoB PCR products of in rifampicin-resistant strains will fail to hybridize to one 
or more of the wild type oligonucleotides, and will in most case show affinity to a mutant 
oligonucleotide. With this method, rifampicin resistance in MTB isolates can be detected 
within a few hours. In principle, the method can also be applied directly to clinical material 
and Ziehl-Neelsen (ZN) slides containing sufficient numbers of acid –fast bacilli, as has been 
demonstrated for spoligotyping, a PCR reverse-line blot assay to detect and type 
M.tuberculosis. 
The accuracy, the high positive predictive value and the high sensitivity of the RIFO assay 
make it a useful tool for the early detection of MDR-TB cases (Morcillo, 2002; Senna, 2006). 
Even starting from early primary cultures, several important weeks can be saved with the 
application of the RIFO assay in comparaison with conventional laboratory methods. 
The cost of the RIFO assay is 10 times lower than that of the commercially available kit to 
determine the RIF resistance of M.tuberculosis complex bacteria. 
Later on, Mokrousov et al (1994) developed a home made reverse line blot (RLB) assay 
targeting a wide range of mutations in six genes (rpoB, inhA, ahpC, rpsL, rrs, embB) associated 
with resistance to four first line anti-TB drugs (RIF, INH, SM and EMB).this macroarray 
based technique presnts in fact a rapid alternative to sequencing and may be recommended 
for use in TB reference laboratories. Its implementation can start with detection of RIF 
resistance as MDR marker and shoud focus on locallypredominant rpoB mutations. It is 
open to further development and it permits easy incorporation of new probes targeting 
mutations related either to newly uncovered mechanisms of resistance to the first-line anti-
TB drugs, or to the second line drugs and newer anti-TB compounds. Analysis of the 
additional genes, such as, gyrA and gyrB (FQ resistance), other rrs mutations in the 530 and 
912 regions (SM resistance), and rpoB mutations outside RRDR, eventually using a multiple 
co-amplification/co-hubridisation approach, seems promising. 
7.2.4 PCR-Single Strand Conformation Polymorphism (PCR-SSCP)  
SSCP is a gel based method that can detect short stretches of DNA approximately 175–250bp 
in size. Small changes in a nucleotide sequence result in differences in secondary structures 
as well as measurable DNA mobility shifts that are detected on a non-denaturing 
polyacrylamide gel.  
PCR-SSCP analysis is increasingly useful. To date various studies have applied PCR-SSCP to 
identify mutational changes associated with drug resistance in M. tuberculosis for frontline 
drugs like, RIF and INH (Kim, 2004; Cardoso, 2004; Fang, 1999; Heym, 1995; Pretorius, 1995) 
In particular, the development of nonisotopic PCR-SSCP analysis has simplified the 
procedure, enhancing its utility in routine laboratories (Kalia, 1997; Lee, 2003). However, 
PCR-SSCP analysis has been found to be technically demanding and not sufficiently 
sensitive. Furthermore SSCP conditions must be carefully evaluated since not all mutations 
will be detected under the same conditions. Also, results obtained with SSCP analysis 
should be interpreted with caution as the technique only detects mutations and gives no 
information on the nature of associated mutation. For example, silent mutations in the rpoB 
gene have been identified that give altered mobility patterns on SSCP analysis but have no 
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association with RIF resistance, which underlines the need for caution in interpreting results 
and phenotypic or genotypic correlation (Kim, 1997). 
7.2.5 PCR-Restriction Fragment Length Polymorphism 
Mutations associated with resistance can be identified by digestion of amplified PCR 
products with a restriction enzyme that cuts at the specific polymorphic DNA sequence 
followed by gel electrophoresis. Since not all mutations result in the gain or loss of a 
restriction site, general use of RFLP to screen for mutations associated with drug resistance 
is limited (Victor et al., 2002). 
7.2.6 Microarrays 
Although technically a solid-phase-type hybridization assay, microarrays, also known as 
biochips, have been proposed as new molecular methods for detecting drug resistance in M. 
tuberculosis. They are based on the hybridization of DNA obtained from clinical samples to 
oligonucleotides immobilized in a solid support, such as miniaturized glass slides. They 
have been mainly used to detect resistance to rifampicin. In a recent evaluation using 
oligonucleotide microarrays for analysis of drug resistance, Gryadunov et al. (2005) has 
detected over 95% rifampicin resistant and almost 80% isoniazid resistant M. tuberculosis 
isolates within 12 h in a sample of drug-resistant isolates and clinical samples. For the time 
being and due to the high cost involved, the use of microarrays for detecting drug resistance 
in TB is still beyond the reach of most clinical mycobacteriology laboratories. 
7.2.7 Line-probe assays 
This technology involves a series of steps including extraction of DNA from mycobacterial 
isolates or directly from clinical specimens, polymerase chain reaction (PCR) amplification 
of nucleic acid sequences, hybridization of labeled PCR products with oligonucleotide 
probes immobilized on a strip, and colorimetric development that allows for lines to be seen 
where the probes are located (hence, the term ‘‘line-probe’’ assay) . 
In 2008, the WHO issued a policy statement regarding the molecular line-probe assays for 
use in detection on M. tuberculosis and for detection of drug resistance.  
The first line-probe assay was the INNO-LiPA Rif TB (Innogenetics NV) (Rossau, 1997). The 
results of clinical evaluations of the assay indicated that it accurately detects resistance to 
rifampin, but some of the evaluations showed that the assay was less sensitive for the 
detection of M. tuberculosis complex. A meta-analysis performed in 2005 showed that 12 of 
14 published studies showed 95% of sensitivity with a specificity of 100% but that, in studies 
in which the assay was applied to clinical specimens, the sensitivity ranged from 80% to 
100%. One study showed that the assay could be used successfully in a resource-poor 
setting, compared with reference laboratories (Wilson, 2011). 
The second line-probe assay was the GenoType MTBDR® developed by Hain Lifescience. 
Initially, this assay was developed as the GenoType MTBDR assay, but early evaluations 
showed that the assay did not detect drug resistance to a satisfactory degree, detecting only 
90%–95% of isolates with rifampin or low-level isoniazid resistance. The assay was 
eventually modified to include detection of more rpoB and inhA mutations under the name 
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GenoType MTBDRplus®. Although 2 evaluations of the new assay showed improvement of 
the detection of isoniazid resistance (Hillemann, 2007), 3 other evaluations showed that 
detection of isoniazid resistance remained suboptimal (particularly for strains with low-
level resistance) (Helb, 2010).  
GenoType MTBDRplus® is a DNA strip test that allows simultaneous molecular 
identification of tuberculosis and the most common genetic mutations causing resistance to 
rifampicin and isoniazid. This technology can diagnose MDR-TB directly from smear-
positive sputum samples, providing results in just five hours - an enormous improvement 
on the 1 to 2 months needed for conventional DST (Figure 3). 
A meta-analysis performed in 2008 confirmed these findings; the assay shows high 
sensitivity and specificity for detecting resistance to rifampin but variable results for 
detecting resistance to isoniazid (Barnard, 2008, Ling, 2008). A second meta-analysis 
performed the subsequent year showed similar results, although in this analysis, the pooled 
sensitivity of the GenoType MTBDRplus assay showed better sensitivity for detecting 
isoniazid resistance (Wilson, 2011). Overall, this genotyping kit is a rapid, manual nucleic 
acid amplification test (NAAT) and capable of both detecting M. tuberculosis and carrying 
out drug susceptibility testing (DST), however, results of studies’ evaluations indicate that 
the assay is of limited use with smear-negative specimens and that detection of isoniazid 
resistance is more variable but generally lower than detection of rifampin resistance 
(Barnard, 2008). 
More recently, another version, named GenoType MTBDRsl®, was developed to detect 
resistance to fluoroquinolones, ethambutol, kanamycin, amikacin and capreomycin. Two 
evaluations of this assay have shown promising but variable results for detection of 
resistance to the second-line drugs (Brossier, 2010). 
As with any new diagnostic test, the impact of GenoType MTBDRplus® Assay will depend 
on the reproducibility of the results under actual field conditions, the manner and extent of 
their introduction, the strength of the laboratories and the degree to which access to 
appropriate therapy follows access to diagnosis. 
LPA is now being rolled out by FIND and partners in 27 high MDR-TB burden countries 
under the EXPANDx-TB programme, supported by UNITAID.  
Currently, the implementation of the GenoType MTBDRplus® as a tool for detection of MDR 
/ XDR strains is under evaluation in two regions of Morocco and is supported by WHO under 
EMRO – COMSTECH projects. The first assay concerned Rabat and neighbours cities which is 
the highest rate of pulmonary tuberculosis in Morocco and containing the major and the 
reference hospital of pulmonary diseases. In fact, this hospital receives patients from hall the 
country and concentrate patients infected with MDR and XDR TB strains 
The second assay concerned Tangier and neighbours cities, with a high prevalence of 
tuberculosis. Moreover, Tangier area has been the theater of a new phenomenon that can 
affect the epidemiology of tuberculosis in this region; immigration from the sub-Saharan 
region to attend Europe. 
We believe that the implementation of the GenoType MTBDRplus® will be of a great 
interest to enhance drug resistant TB diagnosis and therefore to improve TB management in 
Morocco. 
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Fig. 3. Schematic representation of results obtained with the GenoType MTBDRplus® test 
 - : Sensitive strain 
R+I: Strain resistant for both rifampicin and isoniazid,  
I: Strain resistant only for isoniazid 
7.2.8 Cartridge-based automated NAAT 
This assay, usually called Xpert MTB/RIF, is a self-contained and fully automated 
technological platform that integrates sputum processing, DNA extraction and 
amplification, TB and MDR-TB diagnosis. This assay, which was CE (Conformité 
Européenne) marked in 2009, avoids many of the pitfalls of conventional nucleic acid 
amplification tests (Blakemore, 2010; Helb, 2010; Boehme, 2010; Hillemann, 2011). This is 
largely because the device is self-enclosed and, therefore, requires less sophisticated 
infrastructure in terms of laboratory facilities, user training, and supply chain 
management.  
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The assay has recently undergone performance evaluation to detect TB and rifampicin 
resistant strains on respiratory specimens (Wilson, 2011; Helb, 2010; Boehm, 2010; Rachow, 
2011) as well as on non-respiratory samples (Rachow, 2011). The sensitivity of the test to 
detect smear-positive isolates reached 100%. However, the sensitivity for the identification 
of smear-negative culture positive isolates ranged from 71 to 72.5%. Xpert MTB/RIF test 
was shown to be specific in 99.2% of patients without TB. Moreover, its usefulness in 
detecting sputum smear and culture negative patients needs further studies (Helb, 2010; 
Marlowe, 2011). 
On the other hand, and as compared with phenotypic drug-susceptibility testing, Xpert® 
MTB/RIF test was shown to be highly sensitive for detecting rifampin resistance, correctly 
identifying 97.6% of rifampicin-resistant isolates and 98.1% of rifampicin susceptible isolates 
(Boehme, 2010).  
The main disadvantage of this system is the inability to test for and detect isoniazid 
resistance. Other potential disadvantages are related to the cost and a continued need for 
adequate laboratory infrastructure and training of personnel. 
As for GenoType MTBDRplus® test, the Xpert MTB/RIF Assay will depend on the 
reproducibility of the results, the manner and extent of their introduction, the strength of the 
laboratories and the degree to which access to appropriate therapy follows access to 
diagnosis.  
Thus, due to its high sensitivity and specificity, time consuming and the facility to use, the 
Wold Health Organisation endorsed in December 2010 Xpert® MTB/RIF technology and 
released a roadmap to guide its rapid adoption in endemic countries. In this context, the 
Xpert® MTB/RIF technology will be implemented in different cities of Morocco and should 
be used as the initial diagnostic test in individuals suspected of having MDR-TB or HIV-
associated TB and may be considered as a follow-on test to microscopy in settings where 
MDR-TB or HIV is of lesser concern, especially in further testing of smear-negative 
specimens.  
8. The place of molecular approaches in the TB management policy in 
Morocco 
Guidelines for the use of nucleic acid amplification (NAA) tests for the diagnosis of 
tuberculosis (TB) were published in 1996 (CDC, 1996) and updated in 2000 (CDC, 2000). 
Since then, NAA testing has become a routine procedure in many institutions for the 
diagnosis of TB, because NAA tests can rapidly and reliably detect Mycobacterium 
tuberculosis bacteria directly in a specimen one or more weeks earlier than culture. Earlier 
laboratory confirmation of TB can lead to earlier treatment initiation, better patient care and 
outcomes, greater opportunities to interrupt transmission and improved public health 
interventions.  
Guidelines for the use of nucleic acid amplification (NAA) tests for the diagnosis of 
tuberculosis (TB) were published in 1996 (CDC, 1996) and updated in 2000 (CDC, 2000). 
Since then, NAA testing has become a routine procedure in many institutions for the 
diagnosis of TB, because NAA tests can rapidly and reliably detect Mycobacterium 
tuberculosis bacteria directly in a specimen one or more weeks earlier than culture. Earlier 
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laboratory confirmation of TB can lead to earlier treatment initiation, better patient care and 
outcomes, greater opportunities to interrupt transmission and improved public health 
interventions.  
In Morocco, TB biological diagnosis is mainly limited to conventional techniques. These 
techniques (AFB smear, bacterial culture on solid and liquid media) are well established 
across the network of tuberculosis control laboratories. However, 2 laboratories, considered 
as reference laboratories, are authorized to perform drug susceptibility tests to antibiotics. 
According to WHO guidelines, the tested antibiotics are: INH, RIF, SM and EMB.  
In some cases, molecular techniques based on PCR amplification are used to detect TB 
especially in extra-pulmonary tuberculosis. 
Moreover, molecular techniques are well used in research and epidemiology (RFLP, 
spoligotyping, MIRUs,…). Currently, manual and automated techniques based on 
molecular approaches are achievable in some well-equipped laboratories in major centrs in 
Casablanca, Rabat and Tangier. 
As in many developing countries, where the incidence of tuberculosis is declining slowly, 
molecular based tests should be introduced in the national program of Morocco; or at least 
tested for a period to verify the impact of such tests on the annual incidence of tuberculosis. 
In response to a request from many researchers in the field of tuberculosis, an advisory 
council should be set up to evaluate the place of NAA tests in the national program; against 
tuberculosis in Morocco. This committee must include TB clinicians, TB control officials; 
laboratory directors or supervisors from small, medium and large public health laboratories, 
hospital laboratories, and commercial laboratories and representatives from the Regional 
Training and Medical Consultation Centres. This suggestion is based on general 
observations for the use of NAA test to diagnose tuberculosis infections and drug resistance 
of Mycobacterium tuberculosis (CDC, 2009). 
NAA testing has significant potential added value for clinicians and TB control officials.  
a. Earlier diagnosis leads to earlier initiation of treatment, a reduced period of 
infectiousness and improved patient outcomes.  
b. Earlier notification of TB cases to public health authorities should permit public health 
interventions sooner and may engage a TB expert sooner in the care of the TB patient.  
c. Earlier detection of M. tuberculosis bacteria in sputum specimens can facilitate earlier 
infection control (respiratory isolation) decisions.  
d. Earlier differentiation of AFB-smear positive specimens containing M. tuberculosis from 
those containing other Mycobacteria can eliminate unnecessary contact investigations.  
NAA tests can provide substantial savings  
i. for the patient (earlier diagnosis, improved outcomes, reduced health-care costs);  
ii. for the health care provider (definitive diagnosis earlier, focused diagnostic testing, 
optimum patient care);  
iii. for the hospital (less potential for nosocomial transmission, briefer period of respiratory 
isolation if TB is excluded);  
iv. for the public health program (interrupt transmission earlier, abbreviated period for 
transmission, focused contact investigations).  
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For achieving this Implementation, that we believe will have benefic on the national 
program for TB in Morocco, research projects are needed to: 
1. Conduct operational, translational, and implementation research for developing, 
evaluating, and selecting the most effective and efficient NAA testing algorithms for 
routine use and for specific scenarios.  
2. Develop and evaluate suitable tests for use with non-respiratory specimens (e.g., 
cerebrospinal fluid, gastric aspirates, or biopsies).  
3. Develop and evaluate tests that will enhance the diagnosis of TB in children.  
4. Develop and evaluate optimal specimen collection, transport, and processing methods.  
5. Determine the influences of specimen quality and quantity on NAA test performance.  
6. Characterize the ability of NAA tests to detect M. tuberculosis bacteria in mixed 
infections, specimens and cultures.  
7. Develop, evaluate and deploy NAA tests with improved performance and ease-of-use.  
9. Conclusion 
Truly rapid results for drug susceptibility tests are particularly important in the 
management of drug-resistant tuberculosis. Thus, the improvements made by molecular 
biology suggest that effective diagnostic strategies could be used to identify patients with or 
without MDR and even XDR TB strains. However, these techniques suffer from the problem 
that the genetic basis of resistance is not fully understood for any TB drug for all M. 
tuberculosis isolates.  
Conventional techniques will yet be considered as a gold and reference methods. The 
currently available molecular methods may aid in rapid detection of mutations associated 
with drug resistance, but the test results must always be confirmed by phenotypic methods. 
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